With 56088.0 shares changed hands, the volume of the stock remained lighter than its average volume of 0.17 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.09 whereas the lowest price it dropped to was $1.065. The 52-week range on BOLD shows that it touched its highest point at $4.72 and its lowest point at $1.00 during that stretch. It currently has a 1-year price target of $4.00. Beta for the stock currently stands at -0.69.
Price Performance and Earnings:
Three-month performance dropped to -28.19% while six-month performance fell -60.22%. The stock lost -63.10% in the past year, while it has lost -74.46% so far this year. A look at the trailing 12-month EPS for BOLD yields -2.96 with Next year EPS estimates of -2.49. For the next quarter, that number is -0.73. This implies an EPS growth rate of 34.72% for this year and 0.93% for next year.
Float and Shares Shorts:
At present, 22.30 million BOLD shares are outstanding with a float of 14.94 million shares on hand for trading. On 2025-06-13, short shares totaled 0.58 million, which was 260.99999 higher than short shares on 1747267200. In addition to Mr. Zachary Hornby as the firm’s CEO, President & Director, Dr. Christian Hassig Ph.D. serves as its Chief Scientific Officer.
Institutional Ownership:
Through their ownership of 0.70348 of BOLD’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, BOLD reported revenue of $0.0 and operating income of -$17341000.0. The EBITDA in the recently reported quarter was -$17024000.0 and diluted EPS was -$0.71.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With BOLD analysts setting a high price target of 5.0 and a low target of 3.0, the average target price over the next 12 months is 4.0. Based on these targets, BOLD could surge 367.29% to reach the target high and rise by 180.37% to reach the target low. Reaching the average price target will result in a growth of 273.83% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$3.78026 being high and -$3.87974 being low. For BOLD, this leads to a yearly average estimate of -$3.83.
